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We have demonstrated that modifying the tumor microenvironment through intratumoral administration of adeno-
viral vectors (Ad) encoding the conditional cytotoxic molecule, i.e., HSV1-TK and the immune-stimulatory cytokine,
i.e., fms-like tyrosine kinase 3 ligand (Flt3L) leads to T-cell–dependent tumor regression in rodent models of glio-
blastoma. We investigated the role of B cells during immune-mediated glioblastomamultiforme regression. Although
treatment with Ad-TK+Ad-Flt3L induced tumor regression in 60% of wild-type (WT) mice, it completely failed in
B-cell–deficient Igh6−/− mice. Tumor-specific T-cell precursors were detected in Ad-TK+Ad-Flt3L–treated WT mice
but not in Igh6−/− mice. The treatment also failed in WT mice depleted of total B cells or marginal zone B cells.
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948 B Cell Dependent Brain Tumor Regression Candolfi et al. Neoplasia Vol. 13, No. 10, 2011WT mice and in mice with B-cell–specific deletion of Prdm 1 (encoding Blimp-1), in which B cells are present but
unable to fully differentiate into antibody-secreting plasma cells, tumor regression in this model is not dependent
on B cells’ production of tumor antigen–specific immunoglobulins. Instead, B cells seem to play a role as antigen-
presenting cells (APCs). Treatment with Ad-TK+Ad-Flt3L led to an increase in the number of B cells in the cervical
lymph nodes, which stimulated the proliferation of syngeneic T cells and induced clonal expansion of antitumor
T cells. Our data show that B cells act as APCs, playing a critical role in clonal expansion of tumor antigen–specific
T cells and brain tumor regression.
Neoplasia (2011) 13, 947–960Introduction
Glioblastoma multiforme (GBM) is a malignant brain cancer, account-
ing for approximately 50% of newly diagnosed primary brain tumors
in the United States. GBM has a dismal prognosis owing to the local
infiltrative tumor growth that makes complete surgical resection virtu-
ally impossible, the intrinsic radiotherapy and chemotherapy resistance
of glioma cells, and their high rate of mutation. Novel therapeutic
strategies such as vaccination/immunotherapies have been developed
to target GBM cells disseminated throughout the brain [1]. We devel-
oped an anti-GBM immunotherapeutic approach based on engineering
the tumor microenvironment, which uses a combined conditional
cytotoxic/immune–stimulatory gene therapeutic modality. It consists
of an adenoviral vector (Ad) encoding herpes simplex virus type I–
thymidine kinase (Ad-TK), which, in the presence of ganciclovir, kills
proliferating cells, and a second Ad encoding fms-like tyrosine kinase 3
ligand (Ad-Flt3L), which recruits antigen-presenting cells (APCs) to
the brain tumor microenvironment [2]. We have shown that this
combination therapy induces an antitumor immune response and
immunologic memory [2–4]. While the role of cytotoxic T cells in
the clearance of peripheral and brain tumors has been well documented,
the role of B cells in antitumor immunity has remained debatable. This
is due to several reasons: 1) increased numbers of tumor-infiltrating B
lymphocytes can correlate with poor prognosis of patients harboring
metastatic carcinomas [5] or with improved survival of breast carci-
noma patients [6,7]; 2) resting B cells have been implicated in pro-
moting carcinogenesis by exacerbating inflammation [8]; 3) although
B cells are relatively abundant, the frequency of B cells bearing a BcR
specific for a particular antigen is very low (between 10−4 and 10−5),
potentially limiting the effectiveness of B cells as APCs during initial
priming of immune responses [9]; and 4) studies in B-cell knockout
mice revealed that B cells actually suppress the development of immune
responses in vivo against lymphoma, colon cancer, and melanoma
(but not sarcomas) [10,11] and depletion of B lymphocytes enhances
melanoma vaccination efficacy [12], whereas in separate studies,
B lymphocytes were implicated in promoting fibrosarcoma tumor
regression [13].
Bone marrow–derived B cells develop into either follicular B cells or
marginal zone B cells (MZB) in the spleen. Follicular B cells (B220+/
CD23high/CD21low), which account for most peripheral mature B cells,
are found in the circulation, the germinal center of peripheral lymph
nodes (LNs), and the white pulp of the spleen. They participate in
T-cell–dependent immune responses and immunologic memory
[14]. MZB cells (B220+/CD23low/CD21high) are derived from circu-
lating progenitors, but when they arrive to the spleen, they locate inthe marginal zone and do not recirculate; they have been shown to
capture blood-borne antigens and deliver them to dendritic cells
(DCs) of the follicular areas [15]. Also, activatedMZB cells can migrate
to the T-B border and directly induce the expansion of antigen-specific
T cells [16].
Prompted by the central role of B cells in autoimmune diseases
[17–19] and by the successful induction of in vitro T-cell responses
using tumor antigen–pulsed, CD40-activated B cells [20,21], we
investigated the role of B cells in brain tumor regression induced by
intratumoral treatment with Ad-TK+Ad-Flt3L. Using KO mice that
lack B cells and specific antibodies that deplete total B cells or MZB
cells, we found that, in the absence of B cells, Ad-TK+Ad-Flt3L fails
to induce the regression of intracranial GBM. Tumor antigen–specific
T-cell clonal expansion was also abolished in B-cell–deficient mice
(Igh6−/−), indicating that functional, mature B cells were required
for mounting a systemic immune response against brain tumor anti-
gens. The role of B cells in this antitumor immune response does not,
however, seem to be mediated by the production of antitumor-specific
antibodies because we could not detect evidence of humoral antitumor
immunity and the treatment was still efficacious in mice deficient in
plasma cells formation, Prdmflox/floxCD19Cre/+ mice. Although the
most evident function of B cells in adaptive immune responses is the
clonal differentiation of antigen-specific B cells into plasma cells and
the subsequent secretion of antigen-specific immunoglobulin (Ig),
B cells can also function as efficient APCs [9,17,20–22]. Ad-Flt3L/
Ad-TK treatment induced an increase in the levels of B cells in the cer-
vical LNs of WT mice. These B cells contained brain tumor remnants,
increased expression of coactivation markers, and induced the clonal
expansion of syngeneic tumor antigen–specific T lymphocytes. Taken
together, our results imply that B cells may act as APCs to enhance
clonal expansion of tumor antigen–specific T lymphocytes and
T cell–dependent tumor regression within the central nervous system.
Materials and Methods
Ads
First-generation, E1/E3–deleted replication-deficient recombinant
adenovirus serotype 5 was used in this study. We used Ad-Flt3L [3]
and Ad-TK [3]; both transgenes are under the control of human
CMV promoter. An Ad without a transgene was used as a control
(Ad-0). All viral preparations were confirmed to be replication com-
petent adenovirus and lipopolysaccharide (LPS) free. Viral titers were
determined by an end-point dilution cytotoxic-effect assay. Themethods
for Ad generation, purification, characterization, and scale-up have been
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within the intracranial tumors as described below using the following
doses: Ad-TK, 108 infectious units (iu); Ad-Flt3L, 2 × 108 iu; and
Ad.0, 3 × 108 iu (to deliver equivalent total iu).
Mouse Glioma Models
Female C57BL/6 wild-type mice, green fluorescent protein (GFP+/+)
mice, and Igh6−/− on C57BL/6 background were purchased from
Jackson Laboratories (Bar Harbor, ME). Inbred VM/Dk mice were
donated by the McLaughlin Research Institute (Great Falls, MT)
and bred in the CSMC vivarium. Prdm1flox/flox CD19Cre/+ mice that
lack Blimp-1 in B cells were generated as previously described [23] by
crossing mice expressing Cre-recombinase under the control of the
CD19 promoter (CD19Cre/+) [23] with Prdm1flox/flox mice, which have
the prdm-1 locus encoding Blimp-1 flanked by loxP sites [23]. Ex-
perimental mice used in this study were of Prdm1flox/floxCD19Cre/+
genotype. Both the CD19Cre/+ and the Prdm1flox/flox mice were back-
crossed to C57BL/6J 10 times before mating to generate Prdm1flox/flox
CD19Cre/+. Intracranial GBM models were generated as previously
described [2,24]. Mice were stereotactically injected with GBM cells
(either 20,000 GL26 cells, 20,000 GL26-OVA cells [24] [stably ex-
pressing cytoplasmic chicken ovalbumin], or 5000 SMA-560 cells
[25], a gift from Darell Bigner [Duke University]), in a volume of
1 μl into the right striatum (+0.5 mm anterior-posterior, +2.1 mm
medial-lateral, and −3.2 mm dorsoventral from bregma). Fourteen days
later, vectors were administered intratumorally using the same burr hole
(at −2.9, −3.2, and −3.5 mm DV from bregma: 0.5 μl per site). Ganci-
clovir (GCV, 25 mg/kg per day) was administered intraperitoneally (i.p.)
for 7 days after vector administration to all animals receiving Ad-TK. To
assess whether B cells are involved in the memory response elicited by the
combined conditional cytotoxic/immune gene therapy, mice were rechal-
lenged by injection of 20,000 tumor cells in the contralateral brain hemi-
sphere [2]. Mice were killed at specific time points or when their health
status reached criteria established by the guidelines of the Institutional
Animal Care and Use Committee at Cedars-Sinai Medical Center (ap-
proved protocol 2259). Mice were killed under deep anesthesia by termi-
nal perfusion with oxygenated, heparinized Tyrode solution. Blood,
cervical LNs, spleen, and tumors were collected immediately after perfu-
sion and processed for flow cytometric analysis or ELISA. When brains
were analyzed by immunofluorescence, mice were also perfused with 4%
paraformaldehyde (PFA) in phosphate-buffered saline (PBS), and brains
were postfixed in 4% PFA for three additional days.
Generation of Bone Marrow Chimeric Mice
Bone marrow chimeric mice were generated using GFP+/+ and
wild-type C57BL/6 mice as described by us previously [2]. Briefly,
irradiated recipient mice (7 Gy) were adoptively transferred with 107
bone marrow cells from donor mice through tail vein injection. Bone
marrow in the recipients was allowed to reconstitute for 10 weeks
before intracranial implantation of GL26 tumor cells. Tumor-infiltrating
immune cells were purified using Percoll gradient centrifugation as
described below. The origin of tumor-infiltrating B cells (CD19+/
CD45+) was determined by analyzing their relative expression of GFP
by flow cytometry.
B-Cell Depletion Experiments
B-cell depletion. The IgG2a 18B12 monoclonal antimouse CD20
antibody was generated as previously described [26]. The IgG2amouse antihuman 2B8 CD20 monoclonal antibody was used as iso-
type control [26]. The duration of B-cell depletion was assessed in
naive mice injected i.p. with 300 μl of 1 mg/ml antimouse CD20
or isotype control. B-cell content and integrity of T-cell populations
were determined by flow cytometry in spleen 7 or 12 days later. The
integrity of T-cell populations in B-cell–depleted mice was deter-
mined 7 days after depletion using the following antibodies: hamster
antimouse CD3ɛ, rat antimouse CD8α, and rat antimouse CD4
(Table W1). GL26 tumor-bearing mice were injected i.p. with anti-
mouse CD20 on the day of the treatment with Ad vectors and again
2 weeks later to maintain depletion. Animals undergoing rechallenge
experiments received i.p. injections of depleting antibodies on the day
of the rechallenge (day 90) and 2 weeks later (day 105).
MZ B-cell depletion. MZB cells were depleted with 100 μg of anti–
LFA-1 and 100 μg of anti-CD49d [27]. To assess the duration of MZB
cell depletion, naive mice were injected with these antibodies or isotype
controls (TableW1). The content of MZB cells was determined by flow
cytometry in the spleen 3, 7, and 10 days later. The integrity of T-cell
populations in MZB cell–depleted mice was determined 7 days after
depletion using the antibodies indicated above. GL26 tumor-bearing
mice were injected i.p. with anti–LFA-1 and CD49d or isotype controls
on the day of the treatment with Ad vectors and 10 days later.
Isolation and Characterization of Immune Cells in
Brain Tumor, Spleen, and Cervical LNs
Brains were carefully separated from the meninges and removed from
the skull. The tumor was dissected, taking care to avoid the ventricles.
Tumors were homogenized in RPMI medium using a glass Tenbroeck
homogenizer (Kontas Glass Company). To purify mononuclear cells
from the tumor, homogenized tumor tissue was centrifuged through a
Percoll (GEHealthcare, Piscataway, NJ) step gradient (70%-30%Percoll
in PBS) for 20 minutes at 2200 RPM. Immune cells were extracted
from draining cervical LNs by homogenization using a Tenbroeck
homogenizer. Splenocytes were collected by homogenization of whole
spleen followed by incubation in red blood cell lysis buffer ACK
(0.15 mM NH4Cl, 10 mM KHCO3, and 0.1 mM sodium EDTA at
pH 7.2) for 3 minutes on ice. Immune cells were counted and labeled
with the rat IgGs (BD Pharmingen, San Diego, CA) depicted in
Table W1 and dissolved in 1% FBS–0.1 M PBS. Samples were analyzed
using a FACScan Flow cytometer (Beckton Dickinson, Franklin Lakes,
NJ) and Summit software (Cytomation, Inc, Fort Collins, CO).
Immunofluorescence
Coronal sections of PFA-fixed brains (50 μm) were obtained using a
Leica vibratome (Leica Microsystems Heidelberg, Mannheim, Germany).
Sections were incubated in 10mM citrate (60°C) for antigen retrieval, and
immunofluorescence was performed using the antibodies described in
Table W1. Nuclei were stained with 4′, 6-diamidino-2-phenylindole
(DAPI, 5 μg/ml; Invitrogen, Carlsbad, CA), and tissues were mounted
with ProLong Antifade (Invitrogen). Confocal micrographs were obtained
using a Leica confocal microscope TCS SP2 with AOBS equipped with
405-nm violet-diodeUV laser, 488-nm argon laser, and 594-helium-neon
lasers and using a HCX PL APO 63× 1.4 numerical aperture oil objective
(Leica Microsystems Heidelberg, Mannheim, Germany) [28].
Detection of Total IgG
Homogenized splenocytes were collected followed by incubation
in red blood cell lysis buffer ACK and then incubated with RPMI
950 B Cell Dependent Brain Tumor Regression Candolfi et al. Neoplasia Vol. 13, No. 10, 2011alone or in the presence of LPS (10 μg/ml) for 72 hours. After acti-
vation, total IgG levels were determined in 20 μl of cell culture
supernatants using the Easy-Titer Mouse IgG Kit (Pierce, Rockford,
IL) following the manufacturer’s instructions.
Detection of Circulating Antitumor Antibodies
Detection of circulating antitumor antibodies was performed in
mouse serum collected 7 days after Ad-TK+Ad-Flt3L treatment as
previously described [4]. Briefly, cultured GL26, GL26-OVA, and
SMA-560 cells were stained with rat antimouse IgM-fluorescein
isothiocyanate (FITC, 1:50, 553437; BD Pharmingen) or antimouse
IgG-FITC (1:1000, A-11017; Invitrogen). Samples were analyzed
using a FACScan flow cytometer (Beckton Dickinson).
Flt3L ELISA
Detection of Ad-derived human Flt3L and endogenous mouse
Flt3L was performed in serum 7 days after vector injection. Serum
was diluted 1:10 inDulbecco PBS. The expression of human andmouse
Flt3L was determined using species-specific ELISA kits (DFK00 and
MFK00; R&D Systems).
Trafficking of CellTracker Green–Labeled Tumor Antigen
Cells were labeled with CellTracker Green as described previously
[2]. Briefly, 107 GL26 cells were labeled with CellTracker Green
(4 μM). A total of 250,000 cells in 1.5 μl were injected in the brain
striatum of C57BL/6 mice. Mice were treated 2 days later by intra-
tumoral injection of saline or Ad-Flt3L and Ad-TK, and tumor-
infiltrating immune cells and cervical-draining LNs were harvested
2 and 7 days later and processed for flow cytometry.
Syngeneic Mixed Leukocyte Reaction
B cells were purified from the cervical LNs of GL26-OVA tumor-
bearing mice 7 days after the treatment with Ad-TK+Ad-Flt3L or saline
using a pan B-cell isolation kit (130-095-813; Miltenyi Biotec, Bergisch
Gladbach, Germany) in anOctoMACS Separator (Miltenyi Biotec). The
purity of B-cell preparations was more than 95%, as determined by flow
cytometry using antibodies against mouse CD45, mouse CD19, mouse
CD14, andmouse CD3ɛ (TableW1). Enriched B-cell preparations were
incubated with 2 μg/ml OVA323-339, a known H-2
b–restricted OVA
class II epitope [29] for 3 hours at 37°C, followed by incubation with
50 μg/ml mitomycin C for 30 minutes at 37°C to inhibit the proliferation
of B cells in the syngeneic mixed leukocyte reaction (MLR). Splenocytes
were collected from naive OT-II mice, donated by Dr Jonathan Kaye
(Gene Therapeutics Research Institute; Cedars-Sinai Medical Center).
The syngeneicMLRwas performed by incubating 200,000OT-II spleno-
cytes in the presence of increasing ratios of B cells (1:16, 1:8, 1:4, 1:2, and
1:1) for 90 hours. Cell proliferation was determined by the incorporation of
BrdU into nascent DNA strands and assessed by ELISA (BrdU Cell Pro-
liferation Assay, catalog no. 11647229001; Roche, Mannheim, Germany).
Interferon γ ELISPOT
C57BL/6 mice and Igh6−/− mice were implanted with GL26 tumor
cells and treated 14 days later with Ads expressing Ad-Flt3L and Ad-TK
or saline. Mice were killed 7 days later, and splenocytes were collected
as described previously. A total of 1 × 105 splenocytes were plated in
triplicate onto a capture anti–interferon γ (IFNγ) antibody–coated
(1:60; R&D Systems, Minneapolis, MN) 96-well ELISPOT plate
(polyvinylidene fluoride; Millipore, Billerica, MA), and IFNγ secretion
was quantified according to the manufacturer’s protocol. Briefly, 1 × 105splenocytes were stimulated for 24 hours at 37°C in RPMI 1640 me-
dium with or without 1 μg/ml Trp2180-188 peptide (Sigma, Milwaukee,
WI). ConA (1 μg/ml, 4 hours) stimulation of splenocytes served as a
positive control. Plates were vigorously washed with PBS before incuba-
tion with IFNγ detection antibody (1:60; R&D Systems). Twenty-four
hours later, plates were developed after incubation with streptavidin–
horseradish peroxidase (R&D Systems) and visualized by amino ethyl
carbazole (Sigma-Aldrich). Spots were detected and counted using the
KS ELISPOT (version 4.7; Zeiss, Göttingen, Germany).
Statistical Analysis
Sample sizes were calculated to detect differences between groups
with a power of 80% at a 0.05 significance level using PASS 2008
(Power and sample size software; NCSS, Kaysville, UT). Kaplan-Meier
survival curves were analyzed using the Mantel log-rank (GraphPad
Prism version 3.00; GraphPad Software, San Diego, CA). One- or
two-way analysis of variance (ANOVA) followed by the Tukey test
or unpaired two-tailed Student’s t test (NCSS) were used to analyze
ELISPOT, ELISA, and flow cytometry data, as indicated in the figure
legends. When data failed normality test or Levene equal-variance
test, they were square root transformed. Curve inequality in MLR
experiments was assessed using the randomization test (NCSS). P <
.05 was considered the cutoff for significance. All experiments were
performed at least twice to confirm the findings.
Results
Bone Marrow–Derived B Cells Infiltrate Intracranial
Brain Tumors and Are Required for Antitumor
Immunity and Tumor Regression In Vivo
Our previous results show that intratumoral administration of
Ad-Flt3L/Ad-TK leads to a T-cell–dependent antitumor immune
response that induces tumor regression in rodent models of glioblas-
toma [3,4]. Considering that the role of B cells in anti-brain tumor
immunity remains elusive, we aimed to investigate whether B cells play
a role in the generation of adaptive immune responses against brain
tumor antigens (Figure 1A).
Using immunofluorescence techniques followed by confocal micro-
scopy, we detected CD19+ cells within the brain tumor mass in
C57BL/6 bearing syngeneic GL26 tumors (Figure 1B). These findings
are in agreement with the fact that B cells have been found to infiltrate
GBM in humans [30]. To investigate whether the CD19+ cells that
infiltrate the tumor originate from the bone marrow or from the cen-
tral nervous system, we generated bone marrow chimeric mice con-
sisting of bone marrow from wild-type C57BL/6 mice adaptively
transferred into irradiated GFP+/+ mice. We found that only 17.5%
of tumor-infiltrating B cells in chimeric mice were GFP+, which was
only slightly higher than the background observed in WT mice (8%
GFP+ B cells). Therefore, our data suggest that most of the CD19+
infiltrating immune cells in Ad-TK+Ad-Flt3L–treated brain tumors
are bone marrow derived (Figure 1C).
We next evaluated whether B cells are required to induce the anti-
tumor immune response triggered by the treatment with Ad-TK+Ad-
Flt3L. We implanted GL26 tumor in the brain of Igh6−/− mice, which
are deficient in mature B cells, and treated them 14 days later with
Ad-TK+Ad-Flt3L, or saline as a control (Figure 1, D and E). Whereas
in wild-type mice, treatment with Ad-TK+Ad-Flt3L induced tumor
regression and long-term survival in 60% of the animals, the treatment
failed in Igh6−/− mice (Figure 1D). Tallying with these findings, we
Figure 1. Bone marrow–derived B cells infiltrate into tumors and are required for tumor regression. (A) GL26 cells were implanted in the
striatum of wild-type (WT) or Igh6−/− C57BL/6 mice. Mice were treated 14 days later with an intratumoral injection of Ad-TK+Ad-Flt3L
(TK/Flt3L), and as controls, with saline or an empty vector (Ad.0). (B) Representative confocal image shows B cells (CD19, red) infiltrating
the tumors (vimentin, green) 7 days after the treatment. Nuclei were stained with 4′, 6-diamidino-2-phenylindole (blue). Arrows indicate
tumor-infiltrating B cells. Scale bar, 20 μm. (C) Chimeric mice were constructed to assess the origin of CD19+ B cells infiltrating into the
tumor. WT mice were irradiated and reconstituted with bone marrow from transgenic GFP+/+ mice. WT, GFP+/+, and chimeric mice were
implanted with intracranial GL26 tumors 10 weeks after irradiation and treated with Ad-TK+Ad-Flt3L 14 days later. Seven days after the
treatment, tumor-infiltrating GFP+ B cells were quantified by flow cytometry. Representative dot plots show tumor-infiltrating GFP+ B cells
(GFP+, CD19+; green boxes) or GFP− B cells (GFP−, CD19+; black boxes), gated for CD45+ live leukocytes. (D) Kaplan-Meier survival
curves show efficacy of Ad-TK+Ad-Flt3L. *P < .05 versus saline. Mantel log-rank test. (E) Splenocytes were isolated from wild-type
or Igh6−/− mice 7 days after treatment. Cells were incubated with or without Trp2180-188, a GL26 tumor antigen. The frequency of IFNγ-
secreting T cells was assessed by ELISPOT. *P < .05 versus without Trp2180-188 (two-way ANOVA followed by the Tukey test).
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released IFNγ in response to tumor antigen (Trp2180-188, a known
GL26 H-2Kb–restricted tumor antigen) in Igh6−/− mice implanted
with GL26 tumors and treated with Flt3L and TK (Figure 1E). Thus,
our results suggest that B cells mediate clonal expansion of tumor
antigen–specific T cells and subsequent brain tumor regression.Considering that Igh6−/− mice may display other immunologic de-
fects [31] in addition to the lack of mature B cells, we aimed to sub-
stantiate these initial findings by depleting B cells from tumor-bearing
wild-type animals. We first depleted B cells using an antimouse CD20
antibody [26]. CD20 is a B-cell–specific molecule that is first expressed
on the cell surface during the pre-B to immature B-cell transition but
952 B Cell Dependent Brain Tumor Regression Candolfi et al. Neoplasia Vol. 13, No. 10, 2011is lost on plasma cell differentiation [32]; administration of CD20
antibodies does not deplete plasma cells [32]. Administration of anti-
mCD20 to naive mice led to more than 95% depletion of B cells for
at least 3 weeks (Figure 2A) but did not reduce the population of CD8+
or CD4+ T cells in the spleen (Figure W1). Thus, anti-mCD20 was
administered to tumor-bearing mice on the day of treatment, and again
2 weeks later. B-cell depletion did not affect tumor progression in
saline-treated mice, but it severely impaired the efficacy of Ad-TK+Ad-
Flt3L, confirming a critical role for B cells in mediating the antitumor
immune response induced by this treatment (Figure 2B). Because
Ad-TK+Ad-Flt3L gene therapy induces immunologic memory againstFigure 2. B-cell depletion impairs the efficacy of the immunotherapy.
in naive mice injected i.p. with mouse antimouse CD20 antibody (IgG
300 μg). Spleens were collected 7, 14, and 21 days after depletion an
.05 versus isotype control (two-way ANOVA). (B) GL26 cells were im
with an intratumoral injection of Ad-TK+Ad-Flt3L or saline. B-cell dep
Kaplan-Meier survival curves show efficacy of Ad-TK+Ad-Flt3L–treate
Ad-Flt3L–treated wild-type C57BL/6 mice that survived a first intracra
tumor cells 90 days later. B cells were depleted by i.p. injection ofmous
and 2 weeks later. P^ < .05 versus isotype control. Mantel log-rank tethe tumor [2], we investigated whether B cells are involved in the
memory response elicited. We implanted Ad-TK+Ad-Flt3L–treated
long-term survivors with GL26 glioma cells in the contralateral brain
hemisphere and mice did not receive further treatment, except for the
administration of depleting anti-mCD20 (Figure 2C). B-cell depletion
led to significant reduction in the survival of rechallenged mice, suggest-
ing that B cells play an important role in the antitumor immunologic
memory induced by Ad-TK+Ad-Flt3L.
Using flow cytometry analysis, we assessed the content of B cells
(CD45+/B220+) in the spleen of tumor-bearing mice. We did not
find significant changes in the level of B cells when comparing treated(A) Representative dot plots show efficacy of CD20+ cell depletion
2a, 300 μg) or with isotype control (mouse anti-human CD20 IgG2a,
d B cells (CD45+/CD19+) were quantified by flow cytometry. *P <
planted in the striatum of C57BL/6 mice and treated 14 days later
letion was performed at days 14 and 28 after tumor implantation.
d animals. *P < .05 versus saline. Mantel log-rank test. (C) Ad-TK+
nial tumor were implanted in the contralateral striatum with GL26
e anti-CD20 antibody or isotype control on the day of the rechallenge
st.
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levels of MZB cells (B220+/CD21+/CD23-), we found that treatment
with Ad-TK+Ad-Flt3L induced a rapid increase in the levels of MZB
cells in the spleen 7 days after the treatment (Figure 3A); MZB cells
returned to normal levels by day 12 after treatment. In view of these
findings, we aimed to evaluate the role of MZB cells in the antitumoral
effect of Ad-TK+Ad-Flt3L treatment. MZB cells were depleted using
antibodies against LFA-1 and CD49d [27,33]. At 3 and 10 days after
administration in naive mice, these antibodies depleted 95% and 85%
of MZB cells, respectively (Figure 3B), but did not affect the levels of
CD4+ or CD8+ T-cell populations in the spleen (Figure W1). Whereas
MZB cell depletion did not affect tumor progression in saline-treated
mice, it abrogated the antitumor activity of Ad-TK+Ad-Flt3L, suggesting
that MZB cells play a critical role in the antitumor immune response
induced by the treatment (Figure 3C).Effect of B Cells on Ad-TK+Ad-Flt3L–Induced Antitumor
Immunity Is Not Mediated by the Production of
Antitumor Antibodies
Considering that an important function of B cells is to produce anti-
bodies against specific antigens, we next examined whether Ad-TK+Ad-
Flt3L induces a specific, humoral anti-brain tumor immune response.
Therefore, we collected serum from GL26 tumor-bearing mice and
assessed the presence of circulating antitumor antibodies by flow cytom-
etry (Figures 4 and W2). We did not find detectable levels of anti-
GL26 circulating IgMor IgG at either day 7 or day 12 after the treatment.
Also, we did not observe an antitumor humoral immune response when
we assessed the presence of anti–GL26-OVA antibodies in the serum of
GL26-OVA–bearing mice on treatment with Ad-TK+Ad-Flt3L, when
compared with Ad.0 or saline-treated control mice (Figure W3).
To rule out that the lack of antitumor humoral immunity was strain
related, we used an additional intracranial tumor model. Inbred VM/
Dk mice were implanted in the brain with SMA-560 cells [25] and
treated 12 days later with gene therapy. Whereas all the mice that re-
ceived saline or single treatments succumbed to tumor burden by day
30, Ad-TK+Ad-Flt3L treatment led to long-term survival in 50% of
the mice (Figure 4C ). However, when we assessed the presence of
circulating anti-SMA-560 antibodies 7 days after the treatment, we did
not find detectable levels of anti–SMA-560 IgM (Figure 4D) or IgG
(Figure 4E).
To more conclusively establish that the role of B cells in the effi-
cacy of Ad-TK+Ad-Flt3L is not mediated by the production of anti-
bodies, we used an additional KO mouse model in which B cells
cannot differentiate to plasma cells and thus cannot produce IgGs,
that is, Prdm1flox/flox CD19Cre/+ mice that lack Blimp-1 specifically
in B cells. In agreement with previous reports [23], B cells purified from
the spleen of Prdm1flox/flox CD19Cre/+ mice were incapable of immuno-
globulin secretion and expression of CD138 on in vitro stimulation
with LPS (Figure 5A). We found that Ad-TK+Ad-Flt3L led to 50%
long-term survival in both wild-type and Prdm1flox/flox CD19Cre/+ mice
(Figure 5B), suggesting that plasma cells are not required for the efficacy
of this treatment and that the role of B cells in the antitumor immune
response does not involve the production of antibodies in this model.B Cells Containing Tumor Cell Remnants Are Present in the
Draining LNs after Treatment with Ad-TK+Ad-Flt3L
Because we established that Ad-TK+Ad-Flt3L efficacy is dependent
on B-cell function but does not require the production of antitumor im-munoglobulins, we hypothesized that B cells could be acting as APCs.
Because it had been shown that Flt3L can expand B-cell populations
[34,35], we assessed whether Ad-derived Flt3L expressed in the tumor
mass could reach the peripheral circulation and cause an increase of
B cells in the dLN. We detected circulating transgenic Flt3L (human)
within the tumor mass and in the serum of tumor-bearing mice 7 days
after treatment with Ad-TK+Ad-Flt3L (Figure W4).
We next assessed the content and activation status of B cells in the
cervical LNs of GL26 tumor-bearing mice. B-cell levels increased in the
cervical LNs 7 days after intratumoral delivery of Ad-TK+Ad-Flt3L
when compared with control mice (Figure 6A). To assess the activation
status of B cells in the draining LNs, we evaluated the expression levels
of costimulatory molecules CD40 and CD86. Seven days after the
treatment with Ad-TK+Ad-Flt3L, the percentage of both CD40+
(Figure 6B) and CD86+ (Figure 6C ) B cells increased in the cervical
LNs compared with control mice, indicating that B cells were acti-
vated in response to the intratumoral delivery of Ad-TK+Ad-Flt3L.
B cells can capture and present antigen [36,37] directly to T cells
through MHC I [38,39] and II [9,40] after the up-regulation of
coactivation markers on their cell surface [41]. To investigate the
possible role of B cells as APCs in our model, i.e., functioning as
brain tumor APCs in vivo, GL26 tumor cells were labeled with fluo-
rescent CellTracker Green and were implanted in the brain striatum.
We then quantified the total number of B cells in the tumor and
in the draining LNs that were associated with CellTracker Green–
labeled tumor antigen. A subpopulation of tumor-infiltrating B cells
(∼200 cells) from saline-treated animals were labeled with CellTracker
Green, suggesting that they had become associated with GL26 tumor
cell antigens (Figure 6D). Interestingly, a significant increase (two-
fold, P < .05) in the number of tumor-infiltrating B cells associated
with tumor antigen (∼400 cells) was observed in TK/Flt3L–treated
animals (Figure 6D). We also found that treatment with Ad-TK+Ad-
Flt3L induced a significant increase in the number of B cells asso-
ciated with CellTracker Green–labeled tumor cell remnants in the
cervical draining LNs (Figure 6E ), and although in isolation, this
finding does not provide direct evidence for the role of B cells in
antigen uptake and presentation; it demonstrates that B cells have
the ability to engulf tumor antigen and transport it to T-cell–rich areas.B Cells Isolated from the dLN of Ad-Flt3L+Ad-TK–Treated
Animals Stimulate T-cell Proliferation
Up-regulation of activation markers on B cells is required to induce
proliferation of antigen-specific T lymphocytes [42]. We hypothesized
that the expression of activation markers in a subset of B cells could
stimulate the proliferation of syngeneic T cells. As such, we performed
a syngeneic, antigen-specific MLR. We sort-purified B cells (CD45+/
CD19+) from the cervical LNs of GL26-OVA tumor-bearing mice
7 days after treatment with Ad-Flt3L/Ad-TK or saline (Figure 7A). Con-
sidering the small number of B cells loaded with tumor antigen present
in the LNs of treated mice (∼400 cells; Figure 6D), we first pulsed
them with the OVA peptide presented in the context of MHC-II
(OVA323-339) to amplify the signal to be detected by this assay. B cells
were then cocultured with splenocytes from naive OT-II transgenic
mice, which have a T-cell receptor specific for OVA323-339 in the con-
text of I-Ab. B cells isolated from the LNs of Ad-TK+Ad-Flt3L–treated
mice significantly increased the proliferation of OT-II splenocytes
when compared with B cells from saline-treated control mice (Figure 7,
B and C).
Figure 3.MZB cell depletion impairs the efficacy of the immunotherapy. (A) GL26 cells were implanted in the striatum of wild-type C57BL/
6 mice. Mice were treated 14 days later with an intratumoral injection of Ad-TK+Ad-Flt3L, and as controls, with saline or an empty vector
(Ad.0). At 7 and 12 days after the treatment, levels of MZB cells in the spleen were quantified by flow cytometry using anti-B220, anti-CD21,
and anti-CD23 antibodies. *P < .05 versus saline, P^ < .05 versus Ad.0. (B) Representative dot plots show efficacy of MZB cell depletion
in the spleen of naive mice 3, 10, and 20 days after i.p. administration of anti-CD49d antibody (100 μg) and anti-LFA-1 antibody (100 μg)
or the corresponding isotype controls (rat IgG2a and rat IgG2b, 100 μg each). *P < .05 versus isotype control (two-way ANOVA). (C) GL26
cells were implanted in the striatum of C57BL/6 mice and treated 14 days later with an intratumoral injection of Ad-TK+Ad-Flt3L or saline.
MZB cell depletion was performed at days 14 and 24 after tumor implantation. Kaplan-Meier survival curves show efficacy of Ad-TK+Ad-
Flt3L–treated animals. *P < .05 versus saline. Mantel log-rank test.
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Figure 4. Assessment of the antibody response against the tumor. (A and B) GL26 cells were implanted in the striatum of C57BL/6 mice
and treated 14 days later with an intratumoral injection of Ad-TK+Ad-Flt3L, saline, or an empty vector (Ad.0). At 7 (A) and 12 (B) days after
the treatment, serum was collected to evaluate the presence of circulating anti-GL26 cell IgM (A) and IgG (B), respectively. Histograms
and graphs show the fluorescence intensity of fixed GL26 cells that were incubated with normal C57BL/6 serum (red area) or serum from
treated tumor-bearing mice (colored lines), followed by FITC-conjugated antimouse IgM or IgG. (C) Kaplan-Meier survival curves show
the survival of inbred VM/Dk mice bearing intracranial SMA-560 tumors and treated 12 days later with Ad-TK+Ad-Flt3L, saline, or Ad.0.
*P < .05 versus saline (log-rank test). Seven days after the treatment, serum was collected to evaluate the presence of circulating anti–
SMA-560 cell antibodies. (D and E) Histograms and graphs show the fluorescence intensity of fixed SMA-560 cells that were incubated
with normal inbred VM/Dk mouse serum (red area) or serum from treated mice (colored lines), followed by FITC-conjugated antimouse
IgM (D) or FITC–antimouse IgG (E).
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In the present study, we investigated the role of B cells in the im-
mune response induced by Ad-TK+Ad-Flt3L against brain tumors.
Whereas the role of T cells in the clearance of brain and peripheral
tumors has been extensively studied, the involvement of B cells in
antitumor immunity is poorly understood. We demonstrated that
B cells are recruited into the brain tumor microenvironment after
treatment with Ad-TK+Ad-Flt3L and that they can collect antigen,
transport it to the draining LNs, and present it to T cells, playing a
critical role as APCs in the immune response against tumors located
within the brain.Figure 5. Lack of plasma cells does not impair the efficacy of Ad-
TK+Ad-Flt3L. (A) Representative dot plots show the percentage of
B cells (B220+) and plasma cells (B220+CD138+) as assessed
by flow cytometry. Note the lack of plasma cells in Prdm1flox/flox
CD19Cre/+ mice. Splenocytes were collected from wild-type and
Prdm1flox/floxCD19Cre/+ mice and incubated in the presence of 10 μg/
ml LPS for 72 hours. Total IgG levels (IgG1, IgG2, IgG3, and IgG4)
were assessed using an Easy-Titer IgG Assay Kit. (B) Kaplan-Meier
curves show the survival of wild-type or Prdm1flox/floxCD19Cre/+ mice,
which are unable to produce antibodies, that were implanted in the
brain with GL26 cells and treated 14 days later with Ad-TK+Ad-Flt3L
or saline. *P < .05 versus saline. Mantel log-rank test.Using KO mice that are deficient in B cells (Igh6−/−) and B cells’
depleting antibodies, we found that B cells are required for the regres-
sion of intracranial GBM in mice treated with Ad-TK+Ad-Flt3L.
Although administration of anti-CD20 antibody was reported to slow
the growth of peripheral solid tumors and enhance the efficacy of
immunotherapy [43], we found that administration of the anti-CD20
antibody did not affect the growth of untreated intracranial tumors in
C57BL/6 mice and severely impaired the efficacy of Ad-TK+Ad-Flt3L
gene therapy. Thus, although B-cell depletion may be a useful adjunct
in immunotherapy for experimental B-cell lymphomas [44] and multiple
nonhematopoietic solid tumormodels, such as lung carcinoma, thymoma,
and mesothelioma [43], our data suggest that B-cell depletion could be
detrimental when inducing immune responses against tumors located
within the central nervous system. Depletion of MZB cells also impaired
the therapeutic effect of Ad-TK+Ad-Flt3L. MZB cells express high levels
of MHCII and are potent activators of CD4+ T cells [14]. Although in
mice these cells are confined to the spleen, they have an ideal location to
screen and rapidly respond to blood-borne antigens that may be released
from dying tumor cells and to antigens that are transported by DCs [14].
MZB cells can transport IgM-containing immune complexes to follicular
DCs in the initial steps of T-cell–dependent immune responses or can
directly prime naive CD4+ T cells, inducing their differentiation to
effector T cells [16].
Although the antibody-mediated clearance of antigens located in
the brain has been previously reported [45,46], our results indicate that
the role of B cells in the antitumor immune response elicited in the
intracranial tumor models does not seem to be through the production
of tumor-opsonizing immunoglobulins: 1) we could not detect circu-
lating antibodies in syngeneic GBM models using two different mouse
strains, 2) we did not detect antibodies against tumor cells expressing
a highly immunogenic surrogate tumor antigen, 3) the efficacy of Ad-
TK+Ad-Flt3L was not impaired in mice that lack plasma cells, and 4)
the efficacy of Ad-TK+Ad-Flt3L was impaired when mice received anti-
bodies against CD20, which do not deplete plasma cells because of the
loss of CD20 during plasma cell differentiation [32].
B cells can capture and present antigen [36,37] directly to T cells
through MHC I [38,39] and II [9,40] after the up-regulation of co-
activation markers on their cell surface [41]. The major route of antigen
uptake by B cells is through specific binding to the B-cell receptor fol-
lowed by receptor-mediated endocytosis. Antigen is then processed and
loaded onto MHC molecules that are displayed on the B-cell sur-
face. This process of antigen acquisition can be repeated as the B-cell
encounters and binds additional antigen, thereby concentrating extra-
cellular antigen encountered in low abundance, and subsequently pre-
sent them to T cells [9]. B cells can present antigen [36,37] directly to
T cells through MHC I [38,39] and II [9,40] after the up-regulation
of coactivation markers on their cell surface [41]. Although cytotoxic
CD8+ T cells are involved in the immune-mediated rejection of the
intracranial tumors [24], it has been demonstrated that tumor antigen–
specific CD8+ T cells are typically short-lived [47] and sustained
T-cell–dependent immune responses require a concomitant CD4+
T helper response to enhance the longevity of the CD8+ T-cell response
[48]. Herein, we assessed whether B cells purified from the LNs of
OVA-GL26 tumor-bearing mice were capable of antigen presenta-
tion to CD4+ T cells from OT-II transgenic mice. Only B cells from
Ad-TK+Ad-Flt3L–treated mice were capable of providing costimula-
tory signals and tumor antigens supporting syngeneic T-cell prolifera-
tion. Our data suggest that B cells could be acting as APCs, playing
a role in clonal expansion of tumor antigen–specific T lymphocytes.
Figure 6. B cells containing tumor cell remnants migrate to the cervical draining LNs. Wild-type C57BL/6 mice were implanted with GL26
tumors and treated 14 days later with Ad-TK+Ad-Flt3L (Ad.TK/Flt3L), saline, or Ad.0. After 7 days, immune cells isolated from dLN were
analyzed by flow cytometry. Representative dot plots and graphs show the content of B cells (CD19+/CD45+; A) and the percentage of
CD40+ (CD19+/CD45+CD40+; B) and CD86+ B cells (CD19+/CD45+/CD86+; C) in the dLN. *P < .05 versus saline, ^P < .05 versus Ad.0
(one-way ANOVA followed by the Tukey test). (D and E) GL26 cells were labeled with CellTracker Green and implanted in the striatum of
C57BL/6 mice. Two days later, mice were treated with either saline or Ad-TK+Ad-Flt3L and immune cells were isolated from tumors and
draining LNs 7 days later. Representative dot plots and graphs show the content of B cells associated with CellTracker Green+ tumor
protein remnants within the tumors (D) and in the dLN (E). *P < .05 (Student’s t test).
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Figure 7. B cells isolated from the dLN of Ad-Flt3L– and Ad-TK–treated animals stimulate T-cell proliferation. (A) GL26 cells expressing
the surrogate antigen chicken ovoalbumin (OVA) were implanted in the striatum of wild-type C57BL/6 mice and treated 14 days later with
Ad-Flt3L and Ad-TK or saline. Seven days later, B cells were purified from the dLN by MACS. The purity of B-cell preparations was greater
than 95%, as assessed by flow cytometry (B). (C) A syngeneic MLR was used to determine whether B cells could stimulate T-cell prolif-
eration. B cells (stimulators) were primed with OVA, incubated with mitomycin, and then cocultured at different ratios with syngeneic
splenocytes collected from naive OT-II mice (responders) for 72 hours. BrdU incorporation into DNAwas used to determine cell proliferation.
*P < .05 versus saline (randomization test). Inset: splenocytes were incubated in the absence of B cells and in the presence of anti-CD3
antibody (1 μg/ml) or OVA323-339 (2 μg/ml), as positive controls.
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expansion of tumor antigen–specific T cells. An alternative scenario is
that B cells are not involved directly in presenting tumor antigen to
T cells but could provide costimulatory signals to T cells in contact with
DCs. This is supported by other studies that highlight the role of B cells
to enhance the costimulatory signaling between DCs and T cells [49].
We have previously shown that DCs play a pivotal role in the onset of
the antitumor immune response induced by Ad-TK+Ad-Flt3L [2].
Although DCs are the main APCs that trigger adaptive immune re-
sponses [50], increasing evidence suggests that interactions between
DCs and B cells promote optimal T-cell activation. For instance, co-
operation between DC and B cells has been observed to be required for
the presentation of viral antigens to naive, antigen-specific T cells [51].
B cells have been shown to collaborate with DCs in the presentation of
extracellular antigens that trigger the activation of effector T cells and
the generation of memory T cells [49]. Furthermore, B cells have been
shown to modulate the profile of cytokines released by activated DCs[52]. Conversely, DCs have been shown to capture, retain, and transfer
unprocessed antigen to B cells [53]. Also, bidirectional proliferation and
survival signaling have been detected between B cells and DCs [52,54].
Flt3L is a critical cytokine that induces differentiation of B cells
from early hematopoietic stem cell precursors [34]. In our model,
expression of Flt3L within the tumor mass resulted in high levels of
systemic Flt3L, which may be responsible for the expansion of MZB
cells and the increased levels of B cells observed in the dLN of tumor-
bearing mice treated with Ad-TK+Ad-Flt3L. We also observed in-
creased expression of cell surface CD40 and CD86 on B cells in the
dLN, which is indicative that B cells are activated [55] and capable
of acting as tumor APCs [41]. Our data suggests that B cells might
be transporting tumor antigen and promoting T-cell proliferation in
the draining LNs [36,56] after treatment with Ad-Flt3L/Ad-TK. Al-
though the brain lacks classic lymph vessels, the migration of leukocytes
from the brain to the cervical LNs has been shown to occur through
the cribroid plate and the nasal mucosa [57]. Also, it is possible that
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ceptor of B cells can bind soluble antigen, the efficiency of this process
in vivo is very low. Nevertheless, it has been shown that, in the LNs,
B cells can obtain antigens from subcapsular sinus macrophages and
from follicular DCs, which can act as long-term depots for B-cell
antigens [58]. These findings, and the fact that B cells from the LNs
of Ad-Flt3L/Ad-TK–treated mice are able to stimulate the clonal ex-
pansion of syngeneic tumor antigen–specific T cells, strongly support
the notion that B cells could be acting as APCs in this model. Although
the number of B cells associated with tumor cell remnants that we
detected in the cervical LNs (∼400, i.e., ∼60 per 106 cells) during the
antitumor immune response induced by immunotherapy may seem
small, it is in agreement with data from other groups. Lindell et al.
[59] have shown that around 50 antigen-specific B cells/106 total cells
reach the LNs to efficiently present cockroach antigen to T cells during
the onset of allergic lung disease. It has also been demonstrated that
only a few hundred skin-derived DCs are required to make their way
to the draining brachial LN to provide prolonged presentation and
robust levels of CTL expansion [60–62].
Taken together, the results we present in this article strongly sug-
gest that B cells are acting as APCs. The evidence we present here
can be summarized as follows: 1) B cells are required for antitumor
immunity triggered by our treatment because the treatment fails in
B-cell–deficient mice Igh6−/− mice and in wild-type mice that have
been depleted of total B cells or MZB cells; 2) B cells’ role in antitumor
immunity does not depend on antibody production; 3) B cells have the
ability to engulf tumor antigen, transport it to T-cell–rich areas, and
overexpress coactivation markers that support T-cell activation; and
4) pure preparations of B cells from the LNs of Ad-Flt3L/Ad-TK–
treated mice are able to stimulate the expansion of syngeneic tumor
antigen–specific T cells.
The data presented herein indicate that B cells could be useful
therapeutic targets to increase the efficacy of immunotherapeutics for
brain cancer. It has been shown that CD40-activated B cells loaded with
tumor RNA constitute potent antitumor vaccines, which can be readily
generated from small amounts of blood and act as efficient APCs to
drive the activation of antigen-specific T cells [22,63]. TLR9 agonists
have also been shown to stimulate the expression of MHC and co-
activation markers in human B cells, enhancing their ability to cross-
present antigens to autologous T cells [64], and could improve B-cell
vaccine design for brain cancer immune-based therapeutics. Our results
highlight the role of B lymphocytes during immunotherapy-dependent
brain tumor regression and suggest that they could act as APCs, leading
to effective antitumor immunity and immunologic memory.References
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Table W1. Source of Antibodies.Antibody Catalog No.Depletion
Anti–LFA-1 (αLβ2) 553118 (BD Pharmingen)
Anti–CD49d (α4) 553154 (BD Pharmingen)
Rat IgG2a 553927 (BD Pharmingen)
Rat IgG2b 553986 (BD Pharmingen)Flow cytometry
Anti-CD45 560501 (BD Pharmingen)
Anti-CD19 561113 (BD Pharmingen)
Anti-CD138 553714 (BD Pharmingen)
Anti-CD40 558695 (BD Pharmingen)
Anti-CD86 553768 (BD Pharmingen)
Anti-CD21 552957 (BD Pharmingen)
Anti-B220 553138 (BD Pharmingen)
Anti-CD3 553063 (BD Pharmingen)
Anti-CD8 alpha 553035 (BD Pharmingen)
Anti-CD4 553052 (BD Pharmingen)
Anti-CD14 553063 (BD Pharmingen)Immunocytochemistry
Anti-CD19 MCA1439GA (Serotec, Oxford, United Kingdom)
Anti-vimentin NB100-92123 (Novus Biological, Littleton, CO)
Alexa594-conjugated goat anti-rat IgG A-11007 (Invitrogen)
Alexa488-conjugated goat anti-rabbit IgG A-11034 (Invitrogen)
Figure W1. Administration of antimouse CD20 antibodies or MZB depleting antibodies does not deplete T cells. (A) Representative dot
plots show the populations of T lymphocytes in the spleen of naive mice injected i.p. with mouse antimouse CD20 antibody (IgG2a,
300 μg) or with isotype control (mouse anti-human CD20 IgG2a, 300 μg). (B) Spleens were collected 7 days after depletion and total
CD3+ lymphocytes, CD4+ T cells, and CD8+ T cells (CD45+/CD3+ and CD4+ or CD8+, respectively) were quantified by flow cytometry.
(C) Representative dot plots show the populations of T lymphocytes in the spleen of naive mice injected i.p. with anti-CD49d antibody
(100 μg) and anti–LFA-1 antibody (100 μg) or the corresponding isotype controls (rat IgG2a and rat IgG2b, 100 μg each). (D) Spleens were
collected 7 days after depletion, and total CD3+ lymphocytes and CD4 and CD8 T cells (CD45+/CD3+ and CD4+ or CD8+), respectively, were
quantified by flow cytometry.
Figure W2. Assessment of the antibody response against the tumor. GL26 cells were implanted in the striatum of C57BL/6 mice and
treated 14 days later with an intratumoral injection of Ad-TK+Ad-Flt3L, saline, or an empty vector (Ad.0). At 7 (A) and 12 (B) days after the
treatment, serum was collected to evaluate the presence of circulating anti-GL26 cell IgG (A) and IgM (B), respectively. Histograms and
graphs show the fluorescence intensity of fixed GL26 cells that were incubated with normal C57BL/6 serum (red area) or serum from
treated tumor-bearing mice (colored lines), followed by FITC-conjugated antimouse IgM or IgG.
Figure W3. Assessment of the antibody response against tumor cells expressing a surrogate antigen. GL26 cells expressing chicken
ovalbumin (GL26-OVA) were implanted in the striatumof C57BL/6mice and treated 14 days later with an intratumoral injection of Ad-TK+Ad-
Flt3L, saline, or an empty vector (Ad.0). Seven days after the treatment, serum was collected to evaluate the presence of circulating anti–
GL26-OVA cell IgM and IgG. Histograms and graphs show the fluorescence intensity of fixed GL26-OVA cells that were incubated with
normal C57BL/6 serum (red area) or serum from treated tumor-bearing mice (colored lines), followed by FITC-conjugated antimouse IgM
or IgG.
Figure W4. Flt3L expression 7 days after intratumoral delivery of Ad-Flt3L and Ad-TK. (A) GL26 tumor cells were implanted into the striatum
of C57BL/6 mice; tumors were treated 14 days later with saline (S), Ad.0, or Ad-TK+Ad-Flt3L (TF). Levels of Flt3L expressed from the Ad
vector were assessed using an ELISA specific for human Flt3L (transgenic). Levels of endogenous Flt3L were assessed using an ELISA
specific for mouse Flt3L. Serum (A), brain tumors (B), spleen (C), and liver (D) were harvested 7 days after treatment, and both endogenous
and transgenic Flt3L levels were assayed by ELISA. *P < .05 versus corresponding saline. Two-way ANOVA followed by the Tukey test.
